Evidence map›Paper›PMID 40341243›Full record

ReviewNature aging2025

Replacement as an aging intervention.

Sierra Lore, Jesse R Poganik, Anthony Atala, George Church, Vadim N Gladyshev, Morten Scheibye-Knudsen, Eric Verdin

Abstract readReview
In one paragraph

Review in Nature aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sierra LoreBuck Institute for Research on Aging, Novato, CA, USA.ORCID http://orcid.org/0009-0002-8446-8411
Jesse R PoganikBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3098-8550
Anthony AtalaWake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA.
George ChurchBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6232-9969
Vadim N GladyshevBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Morten Scheibye-KnudsenUniversity of Copenhagen, København, Denmark.ORCID http://orcid.org/0000-0002-6637-1280
Eric VerdinBuck Institute for Research on Aging, Novato, CA, USA. everdin@buckinstitute.org.ORCID http://orcid.org/0000-0003-3703-3183

Funding

The role of hyaluronan in longevity and cancer resistance of longest-lived rodentP01AG047200 · NIA · UNIVERSITY OF ROCHESTER · PI Vadim N. Gladyshev · 2014 to 2026
$36.9M
Cellular senescence and Associated Lysosomal Dysfunction in Immune AgingU01AI180158 · NIAID · BUCK INSTITUTE FOR RESEARCH ON AGING · PI Birgit Schilling, Eric M. Verdin · 2024 to 2026
$2.1M
Understanding Interorgan Communication Through Heterochronic Organ TransplantationU01AG086168 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Vadim N. Gladyshev, Stefan Gunther Tullius · 2024 to 2026
$2.0M
NIAID NIH HHS U01 AI180158NIA NIH HHS P01 AG047200NIA NIH HHS U01 AG086168U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1U01AI180158-01
6 · The paper itself

Abstract

Substantial progress in aging research continues to deepen our understanding of the fundamental mechanisms of aging, yet there is a lack of interventions conclusively shown to attenuate the processes of aging in humans. By contrast, replacement interventions such as joint replacements, pacemaker devices and transplant therapies have a long history of restoring function in injury or disease contexts. Here, we consider biological and synthetic replacement-based strategies as aging interventions. We discuss innovations in tissue engineering, such as the use of scaffolds or bioprinting to generate functional tissues, methods for enhancing donor-recipient compatibility through genetic engineering and recent progress in both cell therapies and xenotransplantation strategies. We explore synthetic approaches including prostheses, external devices and brain-machine interfaces. Additionally, we evaluate the evidence from heterochronic parabiosis experiments in mice and donor-recipient age-mismatched transplants to consider whether systemic benefits could result from personalized replacement approaches. Finally, we outline key challenges and future directions required to advance replacement therapies as viable, scalable and ethical interventions for aging.

Indexed as

AgingTissue EngineeringAnimalsHumansMiceTissue Scaffolds

Identifiers

PMID40341243
PMCPMC12871541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.